116 related articles for article (PubMed ID: 20215799)
1. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
3. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
Reck M; Gutzmer R
Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
[TBL] [Abstract][Full Text] [Related]
4. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
5. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
6. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
7. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
8. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
[No Abstract] [Full Text] [Related]
11. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.
Eilers RE; Gandhi M; Patel JD; Mulcahy MF; Agulnik M; Hensing T; Lacouture ME
J Natl Cancer Inst; 2010 Jan; 102(1):47-53. PubMed ID: 20007525
[TBL] [Abstract][Full Text] [Related]
12. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
Wollenberg A; Moosmann N; Klein E; Katzer K
Exp Dermatol; 2008 Sep; 17(9):790-2. PubMed ID: 18503553
[TBL] [Abstract][Full Text] [Related]
13. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers.
Kafatos G; Dube S; Burdon P; Demonty G; Flinois A; Leclerc M; Lowe K; Feudjo-Tepie M; Segaert S
Clin Colorectal Cancer; 2020 Jun; 19(2):100-108.e9. PubMed ID: 32113902
[TBL] [Abstract][Full Text] [Related]
14. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
15. Hospice referral practices for children with cancer: a survey of pediatric oncologists.
Fowler K; Poehling K; Billheimer D; Hamilton R; Wu H; Mulder J; Frangoul H
J Clin Oncol; 2006 Mar; 24(7):1099-104. PubMed ID: 16505429
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
Hurria A; Naeim A; Elkin E; Limaye S; Grover A; Hudis C; Pearce C; Robson M
Crit Rev Oncol Hematol; 2007 Mar; 61(3):255-60. PubMed ID: 17098441
[TBL] [Abstract][Full Text] [Related]
18. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.
Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC
J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with adapalene of cetuximab-induced acneiform eruptions.
Taguchi K; Fukunaga A; Okuno T; Nishigori C
J Dermatol; 2012 Sep; 39(9):792-4. PubMed ID: 22168666
[No Abstract] [Full Text] [Related]
20. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors.
Quinn GP; Vadaparampil ST; Lee JH; Jacobsen PB; Bepler G; Lancaster J; Keefe DL; Albrecht TL
J Clin Oncol; 2009 Dec; 27(35):5952-7. PubMed ID: 19826115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
